⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 15, 2024Open Access

Supplementary Figure S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Authors

HFHuishou FanQingdao University BWBing WangNational University of Defense Technology LSLihui ShiInstitute of Hematology & Blood Diseases Hospital

Abstract

Survival outcomes of the entire patient cohort

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fan et al. (2024) studied this question.

synapsesocial.com/papers/68e73de0b6db6435876b7c56 https://doi.org/10.1158/1078-0432.25415363.v1

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024
2Supplementary Figure S3 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024
3Supplementary Figure S3 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024
4Supplementary Methods S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024
5Supplementary Methods S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024